spravato ketamine - Search News

FDA, ketamine and depression

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

CNN on MSN · 21h

FDA approves standalone use of J&J’s ketamine-derived depression treatment

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.

Fox Business · 1d

J&J's ketamine-derived nasal spray approved by FDA to treat depression

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

NJBIZ4h

J&J’s ketamine-based drug approved as standalone treatment

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

US Weekly on MSN6d

What Celebrities and Doctors Have Said About Ketamine Use: Chrissy Teigen, Matthew Perry, More

Celebrities like Chrissy Teigen and Matthew Perry have been open about using ketamine for their mental health – here's what ...

Inquirer on MSN2d

Controlled drug Ketamine a lifeline for patients with severe depression in S’pore

Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.

Johnson & Johnson Gets FDA OK For Spravato as Monotherapy

J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

FDA, ketamine and depression

Related topics